Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

HCWB

HCW Biologics Inc

3.60

Aug 04 • 3:59 PM ET +0.26 (7.78%)

3.61

Aftermarket • 7:48 PM ET +0.01 (0.28%)

Healthcare Biotechnology USA Nano NASD

Peers: CMMB COCP CVKD HIND INAB LEXX MTVA NCEL OSRH XCUR

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	5.74M
Enterprise Value	11.09M
Income	-18.12M
Sales	6.59M
Book/sh	5.13
Cash/sh	0.77
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	35
IPO	Jul 20, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	0.87
P/B	0.70
P/C	4.67
P/FCF	-
EV/EBITDA	-
EV/Sales	1.68
Quick Ratio	0.09
Current Ratio	0.09
Debt/Eq	1.14
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-56.76
EPS next Y	-2.64
EPS next Q	-1.98
EPS this Y	95.48%
EPS next Y	8.33%
EPS next 5Y	67.95%
EPS past 3/5Y	13.87% -6.63%
Sales past 3/5Y	-79.94% -57.90%
EPS Y/Y TTM	62.82%
Sales Y/Y TTM	356.16%
EPS Q/Q	118.59%
Sales Q/Q	129080.67%
Earnings	May 14 AMC
EPS/Sales Surpr.	184.09% -

Insider Own	9.30%
Insider Trans	232.13%
Inst Own	4.79%
Inst Trans	6.30%
ROA	-67.57%
ROE	-
ROIC	-314.41%
Gross Margin	87.63%
Oper. Margin	-94.15%
Profit Margin	-274.84%
SMA20	0.08%
SMA50	-43.93%
SMA200	-54.05%
Trades

Shs Outstand	1.60M
Shs Float	1.45M
Short Float	2.07%
Short Ratio	0.01
Short Interest	0.03M
52W High	44.10 -91.84%
52W Low	1.50 140.00%
Volatility	19.52% 12.52%
ATR (14)	0.61
RSI (14)	43.35
Beta	2.37
Rel Volume	0.03
Avg Volume	2.02M
Volume	67,904

Perf Week	39.26%
Perf Month	-22.08%
Perf Quarter	46.27%
Perf Half Y	-48.28%
Perf YTD	-38.18%
Perf Year	-85.70%
Perf 3Y	-99.25%
Perf 5Y	-99.70%
Perf 10Y	-
Recom	1.00
Target Price	30.00
Prev Close	3.34
Price	3.60
Change	7.78%

Jul-29-26 09:06AM	HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering (GlobeNewswire)
Jul-23-26 08:00AM	HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027 (GlobeNewswire) -13.90%
Jun-30-26 08:25AM	HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter (GlobeNewswire) -5.06%
Jun-26-26 08:55AM	HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026 (GlobeNewswire) -8.04%
Jun-16-26 07:00AM	HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata (GlobeNewswire) -6.56%
07:45AM	Loading…
May-27-26 07:45AM	HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen (GlobeNewswire) -25.95%
May-21-26 09:53AM	HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules (GlobeNewswire) +6.17%
May-15-26 10:30AM	BC-Most Active Stocks (Associated Press) +262.02%
May-14-26 04:25PM	HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results (GlobeNewswire)
07:30AM	HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies (GlobeNewswire)
Apr-30-26 04:20PM	HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum (GlobeNewswire) +15.63%
Apr-27-26 10:30AM	BC-Most Active Stocks (Associated Press) +16.88%
07:30AM	HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors (GlobeNewswire)
Mar-31-26 05:05PM	HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results (GlobeNewswire) -16.67%
Mar-17-26 07:50AM	HCW Biologics Closes Exclusive Worldwide License for HCW11-006 - A High Potential Fusion Immunotherapeutic (GlobeNewswire) -6.33%
08:00AM	Loading…
Mar-16-26 08:00AM	HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances (GlobeNewswire) +81.19%
Mar-02-26 08:00AM	HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter (GlobeNewswire)
Feb-17-26 09:50PM	HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules (GlobeNewswire) -7.54%
Feb-13-26 08:30AM	HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune (GlobeNewswire) -21.23%
Nov-19-25 08:30AM	HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -17.01%
Nov-18-25 07:25AM	HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease (GlobeNewswire) -21.24%
Nov-14-25 04:44PM	HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results (GlobeNewswire) +20.48%
Nov-10-25 07:00AM	HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire)
Nov-07-25 07:00AM	HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting (GlobeNewswire) -9.04%
Oct-22-25 09:00AM	HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor "What This Means" Segment (GlobeNewswire)
Oct-16-25 09:25AM	HCW Biologics to Participate in the 2025 Maxim Growth Summit (GlobeNewswire) -7.37%
09:15AM	HCW Biologics' Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire)
Sep-30-25 08:45AM	HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor "What This Means" Segment About its Proprietary T-Cell Engager Program (GlobeNewswire)
Sep-18-25 09:15AM	HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing (GlobeNewswire) +5.34%
09:10AM	Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics (PR Newswire)
08:00AM	Loading…
Sep-16-25 08:00AM	HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development (GlobeNewswire) -15.31%
Sep-09-25 08:00AM	HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program (GlobeNewswire) -6.82%
Aug-25-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +60.82%
08:00AM	HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market (GlobeNewswire)
Aug-18-25 02:44PM	HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
Jun-27-25 07:45AM	HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors (GlobeNewswire) +6.64%
Jun-26-25 07:55AM	HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements (GlobeNewswire) -5.17%
Jun-04-25 08:20AM	HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech (GlobeNewswire) -8.36%
May-15-25 06:14PM	HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results (GlobeNewswire) -6.92% +9.15%
May-13-25 08:01PM	HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules (GlobeNewswire) +92.90% -12.34%
08:30AM	HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization (GlobeNewswire)
Apr-01-25 04:35PM	HCW Biologics Announces 1-for-40 Reverse Stock Split (GlobeNewswire)
Mar-28-25 03:30PM	HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results (GlobeNewswire)
Mar-06-25 06:55AM	HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements (GlobeNewswire)
Feb-03-25 07:15AM	HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial (GlobeNewswire) +128.58%
Jan-15-25 07:00AM	HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025 (GlobeNewswire)
Dec-23-24 08:10AM	HCW Biologics Inc. Received NASDAQ Staff Determination Letter (GlobeNewswire) -11.18%
Nov-20-24 01:55AM	HCW Biologics prices $6.9M registered direct offering at $1.03 per share (TipRanks) -13.89%
Nov-18-24 09:27PM	HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules (GlobeNewswire) +320.91% -11.29%
10:15AM	Why Is Penny Stock HCW Biologics Surging On Monday? (Benzinga)
07:00AM	HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate (GlobeNewswire)
Nov-14-24 04:40PM	HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Aug-23-24 04:30PM	HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction (GlobeNewswire) +11.64% -11.21%
Aug-14-24 04:35PM	HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -13.62%
May-15-24 09:53PM	HCWB Stock Earnings: HCW Biologics Reported Results for Q1 2024 (InvestorPlace) -5.17%
04:39PM	HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Apr-01-24 10:53PM	HCWB Stock Earnings: HCW Biologics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -5.71%
04:10PM	HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights (GlobeNewswire)
Nov-14-23 07:00AM	HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights (GlobeNewswire) -17.73%
Nov-08-23 07:30AM	Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting (GlobeNewswire)
Nov-01-23 07:30AM	Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting (GlobeNewswire) -5.36%
Sep-16-23 11:00AM	Insider Buying: CFO Rebecca Byam Acquires 5,000 Shares of HCW Biologics Inc (GuruFocus.com)
Sep-14-23 01:27PM	Insider Buying: CFO Rebecca Byam Acquires 10,000 Shares of HCW Biologics Inc (GuruFocus.com) +5.45%
Sep-09-23 01:00PM	Insider Buying: CFO Rebecca Byam Acquires 10,000 Shares of HCW Biologics Inc (GuruFocus.com)
Sep-06-23 07:30AM	HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 13, 2023 (GlobeNewswire)
Aug-11-23 07:01AM	Daily Vickers Top Insider Picks for 08/11/2023 (Argus Research)
07:00AM	HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-10-23 06:24AM	Daily Vickers Top Insider Picks for 08/10/2023 (Argus Research)
Aug-09-23 06:26AM	Daily Vickers Top Insider Picks for 08/09/2023 (Argus Research)
Aug-08-23 06:28AM	Daily Vickers Top Insider Picks for 08/08/2023 (Argus Research)
Aug-07-23 06:35AM	Daily Vickers Top Insider Picks for 08/07/2023 (Argus Research)
Aug-04-23 07:14AM	Daily Vickers Top Insider Picks for 08/04/2023 (Argus Research) -8.26%
Aug-03-23 07:15AM	Daily Vickers Top Insider Picks for 08/03/2023 (Argus Research)
Aug-02-23 07:52AM	Daily Vickers Top Insider Picks for 08/02/2023 (Argus Research)
Aug-01-23 06:51AM	Daily Vickers Top Insider Picks for 08/01/2023 (Argus Research)
Jul-31-23 06:44AM	Daily Vickers Top Insider Picks for 07/31/2023 (Argus Research)
Jul-28-23 07:58AM	Daily Vickers Top Insider Picks for 07/28/2023 (Argus Research)
Jul-27-23 07:10AM	Daily Vickers Top Insider Picks for 07/27/2023 (Argus Research)
Jul-26-23 01:12PM	Daily Vickers Top Insider Picks for 07/26/2023 (Argus Research)
Jul-25-23 07:16AM	Daily Vickers Top Insider Picks for 07/25/2023 (Argus Research)
Jul-24-23 07:12AM	Daily Vickers Top Insider Picks for 07/24/2023 (Argus Research)
Jul-21-23 07:23AM	Daily Vickers Top Insider Picks for 07/21/2023 (Argus Research)
Jul-20-23 06:55AM	Daily Vickers Top Insider Picks for 07/20/2023 (Argus Research)
Jul-19-23 07:10AM	Daily Vickers Top Insider Picks for 07/19/2023 (Argus Research)
Jul-18-23 06:53AM	Daily Vickers Top Insider Picks for 07/18/2023 (Argus Research)
Jul-17-23 07:10AM	Daily Vickers Top Insider Picks for 07/17/2023 (Argus Research) +5.42%
Jul-14-23 06:50AM	Daily Vickers Top Insider Picks for 07/14/2023 (Argus Research) -8.23%
Jul-13-23 07:02AM	Daily Vickers Top Insider Picks for 07/13/2023 (Argus Research) +6.45%
Jul-12-23 07:22AM	Daily Vickers Top Insider Picks for 07/12/2023 (Argus Research)
Jul-11-23 06:08AM	Daily Vickers Top Insider Picks for 07/11/2023 (Argus Research)
Jul-10-23 06:56AM	Daily Vickers Top Insider Picks for 07/10/2023 (Argus Research)
Jul-07-23 06:28AM	The past year for HCW Biologics (NASDAQ:HCWB) investors has not been profitable (Simply Wall St.)
Jul-05-23 06:46AM	Daily Vickers Top Insider Picks for 07/05/2023 (Argus Research)
Jul-03-23 06:50AM	Daily Vickers Top Insider Picks for 07/03/2023 (Argus Research)
Jun-30-23 06:52AM	Daily Vickers Top Insider Picks for 06/30/2023 (Argus Research)
Jun-29-23 06:49AM	Daily Vickers Top Insider Picks for 06/29/2023 (Argus Research)
Jun-28-23 06:58AM	Daily Vickers Top Insider Picks for 06/28/2023 (Argus Research)
Jun-27-23 06:46AM	Daily Vickers Top Insider Picks for 06/27/2023 (Argus Research)
Jun-26-23 06:41AM	Daily Vickers Top Insider Picks for 06/26/2023 (Argus Research) -5.22%
Jun-23-23 09:24AM	Daily Vickers Top Insider Picks for 06/23/2023 (Argus Research) +12.75%

HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The firm considers age-related low-grade chronic inflammation as a contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.

FounderDr. Hing C. Wong Ph.D.

M.B.A.Ms. Rebecca Byam CPA

Chief Scientific Officer & VP of Clinical OperationsDr. Peter Rhode Ph.D.

J.D.Ms. Nicole Valdivieso Esq.

Senior Vice President of Business DevelopmentMr. Lee D. Flowers

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wong Hing C	Chief Executive Officer	Jul 29 '26	Buy	2.58	23,210	59,998	125,845	Jul 31 04:10 PM
Flowers Lee	SVP of Business Development	Jul 29 '26	Buy	2.58	7,736	19,998	8,691	Jul 31 04:06 PM
GARRETT SCOTT T	Director	Jul 29 '26	Buy	2.58	7,736	19,998	41,644	Jul 31 04:02 PM
Wong Hing C	Chief Executive Officer	May 22 '26	Buy	1.41	113,879	160,000	615,790	May 27 07:26 PM
GARRETT SCOTT T	Director	May 22 '26	Buy	1.41	177,936	250,000	203,441	May 27 07:25 PM
Byam Rebecca	Chief Financial Officer	May 22 '26	Buy	1.41	14,235	20,000	57,245	May 27 07:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HCWB

HCW Biologics Inc

Upgrade your Finviz experience